比较0.1%溴芬酸钠和0.1%吡嘧司特钾治疗过敏性结膜炎的疗效
0575. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis作者机构：Department of OphthalmologyKeio University School of Medicine35 Shinanomachi Shinjuku-ku Tokyo 160- 8582 Japan
出 版 物：《世界核心医学期刊文摘（眼科学分册）》 (Digest of the World Core Medical Journals:Ophthalmology)
年 卷 期：2005年第1卷第6期
页 面：51-52页
学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学]
主 题：溴芬酸钠 吡嘧司特 过敏性结膜炎 对侧眼 裂隙灯检查 客观体征 非甾体抗炎药 抗过敏药
摘 要：Purpose: We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients. Methods: Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment. Results: Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5% ) selected Bromfenac as more effective, nine patients (40.9% ) selected Pemirolast, and three patients found no difference in efficacy between the two drugs. Conclusion: Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.
维普期刊数据库
同方期刊数据库